Fox, Susan H.

The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease

Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 1,141

Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease

Voon, V., & Fox, S. H. (2007) · Archives of Neurology

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 397

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study

Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P. R., Crossman, A. R., & Brotchie, J. M. (2001) · Neurology

Parkinson's Disease Mechanisms and TreatmentsCannabis and Cannabinoid Research

Cited by 349

Small intestinal bacterial overgrowth in Parkinson's disease

Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders

Parkinson's Disease Mechanisms and TreatmentsGastrointestinal motility and disorders

Cited by 274

Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease

Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology

Hallucinations in medical conditionsParkinson's Disease Mechanisms and Treatments

Cited by 266

Initiation of pharmacological therapy in Parkinson's disease: when, why, and how

de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H., & Lang, A. E. (2020) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 200

The serotonergic system in Parkinson's disease

Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology

Parkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

Cited by 195

Canadian guideline for Parkinson disease

Grimes, D., Fitzpatrick, M., Gordon, J., Miyasaki, J., Fon, E. A., Schlossmacher, M., Suchowersky, O., Rajput, A., Lafontaine, A. L., Mestre, T., et al. (2019) · Canadian Medical Association Journal

Parkinson's Disease Mechanisms and TreatmentsClinical practice guidelines implementation

Cited by 173

Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders

Hallucinations in medical conditionsParkinson's Disease Mechanisms and Treatments

Cited by 153

Eligibility criteria for deep brain stimulation in Parkinson’s disease, tremor, and dystonia

Munhoz, R. P., Picillo, M., Fox, S. H., Bruno, V., Panisset, M., Honey, C. R., & Fasano, A. (2016) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Deep Brain Stimulation and Movement DisordersObsessive-Compulsive Spectrum Disorders

Cited by 89

Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome

STEEVES, T., & FOX, S. (2008) · Progress in Brain Research

Obsessive-Compulsive Spectrum DisordersNeurotransmitter Receptor Influence on Behavior

Cited by 79

Parkinson's disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy

FOX, S., CHUANG, R., & BROTCHIE, J. (2008) · Progress in brain research

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 39